Having trouble viewing this email? View in a browser.

You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.

Drug Topics Community Pharmacists' Report

Drug Topics
Community
Pharmacists' Report

DrugTopics.com

September 27, 2011

CONTINUING PHARMACY EDUCATION

Drug Topics and The University of Connecticut School of Pharmacy launch the next generation of learning for pharmacists

Beginning with the September issue, learn about Opioid Pain Management: Balancing Risks and Benefits. You'll earn 2 free CPE credits and enhance your skills with this valuable online benefit.

Click here for more information and to access the program.

CLINICAL NEWS

Anti-nausea drug ondansetron may lead to fatal arrhythmias: FDA

FDA examines the possibility that ondansetron (Zofran, GlaxoSmithKline) may lead to abnormal and potentially fatal heart arrhythmias. » More

Drug Topics Blog

The ongoing conversation about pharmacy schools

Click here.

Survey

If two of the nation's largest PBMs, Express Scripts and Medco, merge, what would be the most significant implication for the industry?

a) Enhanced competition within the industry, resulting in even lower drug costs for PBM payer clients
b) Express Scripts' size advantage could reduce competition and increase long-term costs for payers
c) Increased pressures on retail pharmacies to compete in the market
d) Increased quality of PBM services across the industry as other PBMs strive to stay competitive
e) Minimal, if any

Respond here and see what your colleagues think too.

Want to see the results of our last survey regarding whether your pharmacy imposes a daily quota of filled prescriptions? Click here.

FDA ACTIONS

FDA approves 2 new indications for denosumab

FDA approves 2 new indications for denosumab: To increase bone mass in men and women who are at high risk of fracture and are receiving therapy for 2 specific cancers. » More

PRODUCT RECALL

Qualitest packaging error sparks oral contraceptive recall

Qualitest has issued a nationwide recall of multiple lots of oral contraceptives, due to a packaging error that may result in an incorrect daily regimen and leave women at risk of unintended pregnancy. » More

CLINICAL NEWS

Pain relief inadequate for many patients

Survey: Nearly half of U.S. outpatients receive inadequate relief of moderate-to-severe pain. » More

COMMUNITY PHARMACY

Giant Eagle offers free allergy screenings

Select Giant Eagle pharmacies partnered with Allegra and US Wellness to offer free allergy testing this fall. The screenings covered the 10 most common allergens. » More

OTC PRODUCTS

FDA reminds consumers about approaching Primatene Mist phase-out

Primatene Mist phases out in December. Pharmacists can help inform consumers about their need for alternative inhalers. » More

FDA, USP meet with drugmakers to discuss OTC standards

Drug manufacturers and USP discuss updates to OTC medications; specifically, the need for standards to help ensure the quality of the medications and their ingredients. » More

 
Twitter  

Follow us on Twitter

Voices

DT Blog

JP at Large

View from the Zoo

Viewpoints

Regulatory & Legal

 

Meetings & Events

Digital Edition

View current edition

Cover
 
Powered by Modern Medicine Advanstar Medical Communications Group

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.